Analytomix LLC

Our mission

To devise smart molecules for diagnostic tests and state of the art cancer treatment

Our Technology

At Analytomix, we have developed a modular platform (AptaLinx) for precision cancer drug delivery, built around a simple but powerful concept: use the tumor itself as the trigger for drug release.

The Targeting Vehicle

Our platform is anchored by FDA-approved antibodies that selectively bind to specific cancer cell markers. The antibody acts as the targeting vehicle, dragging the entire therapeutic system directly to the tumor site.

The Aptamer — A Smart Release Mechanism

Aptamers are short nucleic acid sequences designed to bind with high affinity and specificity to a target molecule. In our platform, the aptamer is designed to bind to the antibody — but to detach precisely when the antibody reaches and binds to its cancer cell target. Once detached, the aptamer is digested by naturally occurring nucleases, releasing the therapeutic payload directly at the tumor site.

Payload Delivery

Our platform supports two delivery configurations, which can be used independently or simultaneously:

• The therapeutic drug is covalently linked directly to the aptamer

• The aptamer is attached to a lipid nanoparticle (LNP) that carries the drug — leveraging the same proven delivery technology behind mRNA vaccines

A Smart Regulatory Strategy

By building on FDA-approved antibodies and established chemotherapy drugs, our platform is designed to minimize regulatory risk — accelerating the path from research to clinical application.

Our Team

We are a team of innovative scientists with expertise in different aspects of biomedical sciences. We have joined our efforts and experiences to achieve our mission. Among the members we can mention: